福泰制药 VRTX 深 沪
等待开盘 08-29 09:30:00 美东时间
392.05
+2.970
+0.76%
华盛通- 最 高392.45
- 今 开389.24
- 成交量 152.61万股
- 最 低 388.00
- 昨 收 389.08
- 总市值 1007.57亿
- 52周最高 519.88
- 市盈率 静 --
- 换手率 0.59%
- 52周最低 362.50
- 委 比 -97.37%
- 总股本 2.57亿
- 历史最高 519.88
- 量 比 0.92
- 振 幅 1.14%
- 历史最低 26.50
- 每 手 1
- 风险率 42.91%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025
Vericel Corporation will participate in a fireside chat at the Wells Fargo Healthcare Conference on September 4, 2025. The company is a leading provider of advanced therapies for sports medicine and severe burn care, with products including MACI for knee cartilage repair, Epicel for severe burns, and NexoBrid for eschar removal. A webcast of the presentation will be available on their Investor Relations website.
08-28 12:30
Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025
Vivoryon Therapeutics N.V. will release its H1 2025 financial results and provide an operational update on September 4, 2025. A conference call and webcast will be held at 3:00 pm CEST / 9:00 am EDT for public access. The report and presentation will be available on the company's website.
08-27 05:00
Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Cognition Therapeutics, Inc. has regained compliance with Nasdaq's minimum share price requirement, maintaining a $1.00 closing bid for 10 consecutive business days. The company is a clinical-stage biopharmaceutical firm developing innovative therapies for neurodegenerative disorders, with its lead candidate, zervimesine, currently in Phase 2 studies.
08-26 20:00
Vor Bio to Participate in Upcoming Investor Conferences
Vor Bio, a clinical-stage biotechnology company focused on autoimmune diseases, announced its participation in two upcoming investor conferences. The company will attend Citi's 2025 Biopharma Back to School Conference on September 2nd in Boston and the Baird 2025 Global Healthcare Conference on September 9th in New York. A live webcast of the fireside chat at the Citi conference will be available on their website. Vor Bio is advancing telitacicep...
08-26 12:00
Voyager to Present at Upcoming Investor Conferences
Voyager Therapeutics announced its participation in several upcoming investor conferences to discuss its non-viral delivery platform for neurotherapeutics. The company will present at events including Citi's Biopharma Back to School Conference, Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, Baird Global Healthcare Conference, and H.C. Wainwright Global Investment Conference. We...
08-26 11:00
Vornado Realty Trust to Purchase 623 Fifth Avenue
Vornado Realty Trust agreed to purchase the 623 Fifth Avenue office building for $218 million. The 36-story, 382,500 square foot structure, currently 75% vacant, will be redeveloped into a Class A boutique office building. Vornado expects to close the deal in September 2025 and complete the project by 2027. The property complements Vornado's existing Manhattan assets. The press release also includes forward-looking statements and risk factors.
08-25 12:05
Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
Vivani Medical, Inc. announced that CEO Adam Mendelsohn will present and host partnering meetings at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, in New York. Mendelsohn will discuss Vivani's miniature, ultra-long-acting drug implants, including the advancement of NPM-139, a semaglutide implant for chronic weight management. The presentation will highlight the Company's NanoPortal™ technology, aimed at impro...
08-20 12:30
Vivakor Resets Record Date of Special Dividend of Adapti, Inc. Shares for September 5, 2025
Vivakor, Inc. announced the reset of its special dividend record date to September 5, 2025. Shareholders will receive approximately 0.0079 shares of Adapti, Inc. per Vivakor share, valued at $0.515 million. Adapti, Inc., formerly Scepter Holdings, Inc., filed its Form 10 with the SEC and acquired The Ballengee Group, a sports management agency representing 200 professional athletes. Vivakor provides energy transportation, storage, reuse, and reme...
08-19 22:18
$166亿“新药王”亮相，减重“黑马”暴涨223%，六大中国制药巨头强势登榜
精彩内容 8月中下旬，跨国药企2025半年报披露接近尾声，2025H1全球畅销药TOP10随之浮出水面。据梳理，司美格鲁肽全球销售额超166亿美元，首次登顶“药...
08-19 16:14
